Therapeutic Advances in First-Line Management of Acute Myeloid Leukemia
Open Access
- 1 November 2019
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 17 (11.5) , 1441-1443
Abstract
Over the past several years, drug approvals for first-line treatment of acute myeloid leukemia have changed the landscape from a “wasteland” to an “embarrassment of riches.” In general, patients deemed “fit” for induction chemotherapy who have a core-binding factor abnormality should receive 7 + 3 in combination with gemtuzumab, 7 + 3 with midostaurin for those with an FLT3 abnormality, and liposomal cytarabine + daunorubicin for patients with secondary AML. Although other options exist, Dr. Daniel A. Pollyea recommended a venetoclax/azacitidine regimen for newly diagnosed “unfit” patients. Future research should focus on more clearly determining the definition of a “fit” patient, he said at the NCCN 2019 Annual Congress: Hematologic Malignancies.Keywords
This publication has 7 references indexed in Scilit:
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II StudyJournal of Clinical Oncology, 2019
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemiaLeukemia, 2019
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeLeukemia, 2018
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJournal of Clinical Oncology, 2018
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3MutationNew England Journal of Medicine, 2017
- Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United StatesAnnals of Hematology, 2015
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trialsThe Lancet Oncology, 2014